Stock EGRX EAGLE PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Eagle Pharmaceuticals, Inc.

Equities

EGRX

US2697961082

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-07-05 pm EDT 		5-day change 1st Jan Change
5.5 USD 0.00% Intraday chart for Eagle Pharmaceuticals, Inc. -1.79% +5.16%
Jul. 01 Eagle Pharmaceuticals, Inc.(NasdaqGM:EGRX) dropped from Russell Small Cap Completeness Index CI
Jul. 01 Eagle Pharmaceuticals, Inc.(NasdaqGM:EGRX) dropped from Russell 2000 Index CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Eagle Pharmaceuticals, Inc.(NasdaqGM:EGRX) dropped from Russell Small Cap Completeness Index
CI
Eagle Pharmaceuticals, Inc.(NasdaqGM:EGRX) dropped from Russell 2000 Index
CI
Eagle Pharmaceuticals, Inc.(NasdaqGM:EGRX) dropped from Russell 2000 Value Index
CI
Eagle Pharmaceuticals, Inc.(NasdaqGM:EGRX) dropped from Russell 3000 Value Index
CI
Eagle Pharmaceuticals, Inc.(NasdaqGM:EGRX) dropped from Russell 2500 Value Index
CI
Eagle Pharmaceuticals, Inc.(NasdaqGM:EGRX) dropped from Russell 2000 Value-Defensive Index
CI
Eagle Pharmaceuticals, Inc.(NasdaqGM:EGRX) dropped from Russell 2000 Dynamic Index
CI
Eagle Pharmaceuticals, Inc.(NasdaqGM:EGRX) dropped from Russell 3000E Index
CI
Eagle Pharmaceuticals, Inc.(NasdaqGM:EGRX) dropped from Russell 2500 Index
CI
Eagle Pharmaceuticals, Inc.(NasdaqGM:EGRX) dropped from Russell 3000 Index
CI
Eagle Pharmaceuticals, Inc.(NasdaqGM:EGRX) dropped from Russell Small Cap Comp Value Index
CI
Eagle Pharmaceuticals, Inc.(NasdaqGM:EGRX) dropped from Russell 3000E Value Index
CI
Eagle Pharmaceuticals, Inc.(NasdaqGM:EGRX) dropped from Russell 2000 Defensive Index
CI
Eagle Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq
AQ
Eagle Pharmaceuticals, Inc. Enters into a Third Amendment to Third Amended and Restated Credit Agreement
CI
North American Morning Briefing : Stock Futures -2-
DJ
Eagle Pharmaceuticals Announces a Trial in Progress Presentation of Phase 2/3 Study of Intravenous Amisulpride as Prevention of Postoperative Nausea and Vomiting in Pediatric Patients at the Upcoming Society for Ambulatory Anesthesia (SAMBA) 2024 Annual Meeting
AQ
North American Morning Briefing : Investors Brace -2-
DJ
North American Morning Briefing : Stock Futures -2-
DJ
Eagle Pharmaceuticals to Present Additional Data from Phase III Trial Demonstrating Sustained Response of Amisulpride for the Rescue Treatment of Postoperative Nausea and Vomiting
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. EGRX Stock
  4. News Eagle Pharmaceuticals, Inc.